Phase 2
Completed N=128
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Source: ClinicalTrials.gov NCT03148795 ↗Enrolled (actual)
128
Serious AEs
40.2%
Results posted
Sep 2021
Primary outcomePrimary: Best Objective Response Rate (ORR) — 29.8 Percentage of participants
Summary
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Best Objective Response Rate (ORR) |
29.8 | — |
| SECONDARY Time to Objective Response |
3.4 | — |
| SECONDARY Duration of Response (DOR) |
12.8 | — |
| SECONDARY Percentage of Participants With Prostate-Specific Antigen (PSA) Response of Greater Than or Equal to (>=) 50 Percentage (%) |
45.8 | — |
| SECONDARY Percentage of Participants With Conversion of Circulating Tumor Cell (CTC) Count |
63.6 | — |
| SECONDARY Percentage of Participants With a Null CTC Count |
53.3 | — |
| SECONDARY Percentage of Participants With Baseline CTC Count <5 CTC Showed Increased CTC Counts at Any Time on Study |
37.9 | — |
| SECONDARY Time to Prostate-Specific Antigen (PSA) Progression |
9.2 | — |
| SECONDARY Radiographic Progression-Free Survival (PFS) |
5.6 | — |
| SECONDARY Overall Survival (OS) |
16.9 | — |
| SECONDARY Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
125 | — |
| SECONDARY Number of Participants With Permanent Treatment Discontinuation Due to Adverse Events |
21 | — |
| SECONDARY Number of Participants With Clinically Significant Abnormalities in Vital Signs |
0; 0; 0; 0; 17; 0 | — |
| SECONDARY Number of Participants With Shift in Laboratory Parameter Values (Hematology) From Grade Less Than Equal to (<=) 2 at Baseline to Grade 3 or 4 Post-baseline |
30; 1; 23; 0; 11; 3 | — |
| SECONDARY Number of Participants With Shift in Laboratory Parameter Values (Chemistry) From Grade <=2 at Baseline to Grade 3 or 4 Post-baseline |
0; 9; 0; 0; 2; 1 | — |
| SECONDARY Number of Participants With Dose Modification |
37 | — |
| SECONDARY Time to Deterioration in Pain Symptom Scores |
NA | — |
| SECONDARY Change From Baseline in Participant Reported Pain Scores Per BPI-SF Question 3 |
-0.51; -1.39; -1.20; -1.25; -0.85; -1.06 | — |
| SECONDARY Change From Baseline in European Quality of Life 5-Domain 5-Level Scale (EQ-5D-5L) Visual Analogue Scores (VAS) |
4.16; 4.44; 6.61; 6.18; 7.68; 7.84 | — |
| SECONDARY Number of Participants With 5 Response Levels for EQ-5D-5L Mobility Domain |
30; 29; 25; 12; 0; 36 | — |
| SECONDARY Number of Participants With 5 Response Levels for EQ-5D-5L Self-Care Domain |
65; 18; 9; 3; 0; 63 | — |
| SECONDARY Number of Participants With 5 Response Levels for EQ-5D-5L Usual Activity Domain |
33; 30; 19; 10; 4; 33 | — |
| SECONDARY Number of Participants With 5 Response Levels for EQ-5D-5L Pain and Discomfort Domain |
15; 35; 30; 16; 0; 25 | — |
| SECONDARY Number of Participants With 5 Response Levels for EQ-5D-5L Anxiety and Depression Domain |
48; 30; 18; 0; 0; 45 | — |
| SECONDARY Pre-dose Plasma Concentration (Ctrough) of Talazoparib |
2631.898; 4748.147; 4213.250; 4378.123 | — |
| SECONDARY Post-dose Plasma Concentration (Ctrough) of Talazoparib |
2289.540; 10713.918 | — |
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age.
- Histologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features.
- Patients must have measurable soft tissue disease per RECIST 1.1
- DNA damage repair deficiency as assessed centrally by a gene mutation biomarker panel (testing of de novo or archival tumor tissue (via central laboratory) or prior historical testing (with Sponsor approval) using the Foundation Medicine, FoundationOne CDx™ NGS gene panel test.
- Consent to a saliva sample collection for a germline comparator, unless prohibited by local regulations or ethics committee (EC) decision.
- Serum testosterone ≤ 1.73 nmol/L (50 ng/dL) at screening.
- Bilateral orchiectomy or ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical castration).
- Progressive disease at study entry defined as 1 or more of the following 3 criteria:
- A minimum of 3 rising PSA values with an interval of at least 1 week between determinations. The screening central laboratory PSA value must be ≥ 2 μg/L (2 ng/mL) if qualifying solely by PSA progression.
- Soft tissue disease progression as defined by RECIST 1.1.
- Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions on bone scan.
- Metastatic disease.
- Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based regimen for metastatic (non castrate or castrate) prostate cancer. Patients may have received radium-223 and/or cabazitaxel, or were deemed unsuitable, declined, or did not have access to these therapies.
- Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC.
- Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before day 1 for patients receiving these therapies.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Estimated life expectancy of ≥ 6 months as assessed by the investigator.
- Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements.
- Must use a condom when having sex from the time of the first dose of study drug through 4 months after last dose of study drug. A highly effective form of contraception must be used from the time of the first dose of study drug through 4 months after last dose of study drug when having sex with a non pregnant female partner of childbearing potential.
- Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.
- Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria
- 1. Use of systemic chemotherapeutic (including but not limited to taxanes), hormonal, biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist) or any other investigational agent within 4 weeks before day 1.
- Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone chemotherapy. Patients who discontinued prior platinum based chemotherapy <=6 months prior to screening or whose disease previously progressed on platinum based therapy at any time in the past are also excluded.
- Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within 4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during study participation
- Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) before day 1.
- Major surgery within 2 weeks before day 1.
- Clinically significant cardiovascular disease.
- Significant ren
Data sourced from ClinicalTrials.gov (NCT03148795). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.